Jefferies Upgrades PTC Therapeutics (PTCT) to Buy, 'deep dive suggests Sephience should continue to beat expectations'
Jefferies analyst Faisal Khurshid upgraded PTC Therapeutics (NASDAQ: PTCT) from Hold ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)